CHRS Coherus BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CHRS

Price (delayed)

$1.26

Market cap

$194.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.06

Enterprise value

$149M

?
Relative Growth: Rel. Growth: 28
Relative Strength: Rel. Strength: 24
Relative Valuation: Rel. Valuation: 14
Relative Profitability: Rel. Profitability: 12

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is ...

Highlights
The gross profit has soared by 75% YoY and by 10% from the previous quarter
The revenue has surged by 61% year-on-year and by 9% since the previous quarter
The net income has plunged by 174% YoY and by 171% from the previous quarter
Coherus BioSciences's EPS has shrunk by 168% YoY and by 165% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.coherus.com
Peers: AMGN RGEN AGEN SRPT

Key stats

What are the main financial stats of CHRS

CHRS stock price

How has the Coherus BioSciences stock price performed over time
Intraday
-3.08%
1 week
3.28%
1 month
-11.27%
1 year
-19.23%
YTD
-11.27%
QTD
-10%

Financial performance

How have Coherus BioSciences's revenue and profit performed over time
Revenue
$50.94M
Gross profit
$35.11M
Operating income
-$158.7M
Net income
-$132.13M
Gross margin
68.9%
Net margin
-259.4%
The net income has plunged by 174% YoY and by 171% from the previous quarter
The net margin has dropped by 165% since the previous quarter and by 146% year-on-year
The gross profit has soared by 75% YoY and by 10% from the previous quarter
The revenue has surged by 61% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does CHRS's price correlate with its fundamentals

Growth

What is Coherus BioSciences's growth rate over time

Valuation

What is Coherus BioSciences stock price valuation
CHRS P/E details
P/E
N/A
P/B
3.19
P/S
3.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.93
Coherus BioSciences's EPS has shrunk by 168% YoY and by 165% QoQ
The equity has contracted by 49% YoY and by 23% from the previous quarter
The price to book (P/B) is 14% more than the last 4 quarters average of 2.9
The revenue has surged by 61% year-on-year and by 9% since the previous quarter
The P/S is 32% above the 5-year quarterly average of 3.0 but 14% below the last 4 quarters average of 4.6

Efficiency

How efficient is Coherus BioSciences business performance
The return on assets has dropped by 185% since the previous quarter
CHRS's return on equity has dropped by 185% since the previous quarter
Coherus BioSciences's return on sales has shrunk by 158% QoQ and by 140% YoY
CHRS's return on invested capital has dropped by 105% since the previous quarter

Dividends

What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CHRS.

Financial health

How did Coherus BioSciences financials performed over time
The total assets is 47% more than the total liabilities
The company's total liabilities has shrunk by 59% YoY and by 30% QoQ
The total assets has plunged by 56% YoY and by 28% from the previous quarter
The debt is 39% smaller than the equity
The debt to equity has soared by 85% YoY and by 27% from the previous quarter
The equity has contracted by 49% YoY and by 23% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.